Abstracts tagged "fibromyalgia"

Abstract Number: 2236 • ACR Convergence 2022
Association of microRNA-30b Plasma Expression with Fibromyalgia Clinical Features and with Corneal Small Nerve Fiber Pathology
Laura Aline Martínez Martínez¹, Fausto Sánchez Muñoz¹, Manuel Ramírez Fernández², Yaneli Juárez Vicuña¹, Mario Peña-Peña¹, Carlos Alfonso Guzman Martin¹, Itzel Palafox Sosa¹ and Manuel Martínez-Lavín¹, ¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ²APEC Hospital de la ceguera, Ciudad de México, Mexico
Background/Purpose: There is a clear association between fibromyalgia and small fiber neuropathy. Dorsal root ganglia contain the small nerve fiber nuclei. Severe fibromyalgia is associated…
Abstract Number: 1218 • ACR Convergence 2022
Prevalence and Impact of Widespread Pain and Fibromyalgia on Measurement of Disease Severity in Psoriatic Arthritis: Lessons from the CorEvitas Registry
Philip J Mease¹, Alexis Ogdie², Dimitrios Pappas³, George Reed⁴ and Joel Kremer⁵, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³CorEvitas, LLC, Waltham, MA, ⁴The Corrona Research Foundation and University of Massachusetts, Albany, NY, ⁵The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Fibromyalgia (FM) occurs concomitantly with inflammatory rheumatic disease, including psoriatic arthritis (PsA), in up to 20% of patients and chronic widespread pain (CWP) in…
Abstract Number: 2256 • ACR Convergence 2022
Increased Brain Functional Connectivity to the Insula Is Associated with Nociplastic Pain in Psoriatic Arthritis
Flavia Sunzini¹, Kristian Stefanov¹, Salim Al-Wasity¹, Steven E Harte², Richard E Harris², Daniel J Clauw², Stefan Siebert³, Carl Goodyear¹, Gordon Waiter⁴ and Neil Basu¹, ¹University of Glasgow, Glasgow, Scotland, United Kingdom, ²University of Michigan, Ann Arbor, MI, ³Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴University of Aberdeen, Aberdeen, Scotland, United Kingdom
Background/Purpose: Pain is a hallmark feature of psoriatic arthritis (PsA); however, its apparent multi-factorial nature makes it difficult for rheumatologists to assess and manage. Clinically,…
Abstract Number: 1219 • ACR Convergence 2022
Gender-Related Clinical Profile of Fibromyalgia Patients
Mark Berman¹, Liane banon², Omer Shlezinger³, Laurence Mangel⁴, Jacob Ablin¹ and Valerie Aloush⁵, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Department of Gastroenterology and Hepatolgy, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Internal Medicine F, Tel Aviv, Israel, ⁴Sackler faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Fibromyalgia is a chronic pain disorder characterized by widespread pain, fatigue, sleep disturbances, cognitive dysfunction and frequent psychiatric comorbidities. Estimated prevalence of fibromyalgia is…
Abstract Number: 1220 • ACR Convergence 2022
Autonomic Dysfunction in Sjogren’s Disease
Ardy Fenando¹, Jordan Estes¹, Maha Mohamad¹, Sareena Shah², John Lee², Duaa Jabari¹, Joshua Baker³ and Ghaith Noaiseh¹, ¹University of Kansas Medical Center, Kansas City, KS, ²University of Missouri-Kansas City, Kansas City, MO, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Sjogren's Disease (SjD) is a heterogenous autoimmune disease associated with debilitating symptoms. Autonomic dysfunction (AD) is common in SjD and may contribute to symptom…
Abstract Number: 1221 • ACR Convergence 2022
Multi-Center Validation of Cell-Bound Complement Activation Products and a Multianalyte Assay Panel Distinguishing Systemic Lupus Erythematosus from Primary Fibromyalgia
Mark Rudolph¹, Scott Rey¹, Alan Kivitz², Stuart Silverman³, Roland Staud⁴ and Roberta Alexander¹, ¹Exagen, Inc., Vista, CA, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴University of Florida, Gainesville, FL
Background/Purpose: A 2016 article in Lupus Science & Medicine (Wallace et al. 2016) described the ability of cell-bound complement activation products (CB-CAPs) on their own--…
Abstract Number: 1222 • ACR Convergence 2022
Association of Fibromyalgia, PTSD and Combat Deployments in Active Duty Military
James Dizmang¹ and Jeanne Tofferi², ¹US Air Force, Vacaville, CA, ²US Army, Ft Sam Houston, TX
Background/Purpose: Many combat veterans experience unexplained symptoms with long-term disability including chronic pain, irritability, headaches, fatigue, behavioral health conditions, and memory difficulty. These invisible wounds…
Abstract Number: 1224 • ACR Convergence 2022
‘No Route Map’: The Complex Healthcare Journeys of People with Fibromyalgia – a Record Linkage Study in the UK
Rosemary Hollick, Ka-Kin Lam, Marcus Beasley, Gareth Jones, Corri Black and Gary Macfarlane, University of Aberdeen, Aberdeen, Scotland, United Kingdom
Background/Purpose: Healthcare services for persons with fibromyalgia (FM) lack co-ordination. Patients describe feeling 'invisible' within healthcare systems and often report poor experiences of care, particularly…
Abstract Number: 1225 • ACR Convergence 2022
Sphygmomanometry for Fibromyalgia Detection in a Rheumatology Outpatient Clinic. a Cross-sectional Study
Viridiana Del Río Guerrero¹, Laura Aline Martínez Martínez¹, Karina Arias Callejas¹, Natalia Carbonell-Bobadilla², Alejandra Mejía Segura¹, Gibrán Azamar Morales¹, Alejandra Espinosa Orantes¹, Mauricio Mora Ramírez¹, Fernanda Mejía Ávila¹, Raúl Molina Sánchez¹, Angélica Vargas-Guerrero¹, Luis H Silveira¹ and Manuel Martínez-Lavín³, ¹Instituto Nacional de Cardiología, Ciudad de México, Mexico, ²National Institute of Cardiology Ignacio Chávez, Ciudad de México, Mexico, ³Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico
Background/Purpose: Allodynia is a key fibromyalgia (FM) feature. Women suffering from FM display more often sphygmomanometry-elicited allodynia when compared to women with osteoarthritis, rheumatoid arthritis…
Abstract Number: 0477 • ACR Convergence 2021
TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial
Gregory Sullivan¹, Mary Kelley², Annabelle Iserson¹, Perry Peters², Ashild Peters², Candace Flint¹, Judy Gendreau³, Herb Harris¹, Ben Vaughn⁴ and Seth Lederman⁵, ¹Tonix Pharmaceuticals, Inc., Chatham, NJ, ²Tonix Pharmaceuticals, Inc., San Diego, CA, ³Gendreau Consulting, LLC, Poway, CA, ⁴Rho, Inc., Cary, NC, ⁵Tonix Pharmaceuticals, Inc., South Dartmouth, MA
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain, fatigue, and nonrestorative sleep, a symptom constellation suggestive of a pathological disturbance in central pain processing…
Abstract Number: 0659 • ACR Convergence 2021
Understanding the Rheumatologic Population We Serve Through Objective Analysis of Referrals and Diagnoses: Does Perception Match Actual Data?
Kirsten Koons¹, Jonida Cote², Sanjeev Shrestha³, Melissa Band³, David Pugliese⁴ and Eric Newman³, ¹Geisinger Medical Center, Lewisburg, PA, ²Geisinger Medical Center, Orefield, PA, ³Geisinger Medical Center, Danville, PA, ⁴Geisinger Medical Center, Wilkes Barre, PA
Background/Purpose: Healthcare access in our Rheumatology Department is challenging. Fibromyalgia is perceived to occupy a large portion of clinic visits, leading to increased wait times…
Abstract Number: 0748 • ACR Convergence 2021
Performance of Standardized Scores for Disease Assessment and Pain in Patients Withspondyloarthritis and Fibromyalgia
Xenofon Baraliakos, Styliani Tsiami, Maria Claudia Gkelaki, Piet Dukatz, Uta Kiltz and Jürgen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The pathogenesis of spondyloarthritis (SpA) including axial SpA (axSpA) and psoriatic arthritis (PsA) differs from fibromyalgia (FM). However, symptoms partially overlap and both patient…
Abstract Number: 0872 • ACR Convergence 2021
Lack of Association Between Cognitive Test Performance and Cognitive Symptoms in Systemic Lupus Erythematosus (SLE)
Sudha Raghunath¹, Yifat Glikmann-Johnston¹, Emma Guymer¹, Eric Morand², Julie Stout¹ and Alberta Hoi³, ¹Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ³Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
Background/Purpose: Cognitive dysfunction (CD) is reported to affect approximately 40% of SLE patients (1). Mood disorders have been associated with both cognitive symptoms and cognitive…
Abstract Number: 0118 • ACR Convergence 2021
Multidimensional Phenotypes of Sleep Quality Using the Pittsburg Quality Sleep Index and Associations Among Sleep Dimensions and Symptoms in Women Diagnosed with Fibromyalgia
Victoria Menzies, Debra Lynch Kelly and Miichael Weaver, University of Florida, Gainesville, FL
Background/Purpose: There are over 10 million people in the United States suffering with fibromyalgia syndrome (FMS). Individuals with FMS typically report multiple concurrent symptoms including…
Abstract Number: 0119 • ACR Convergence 2021
Worsened Depression but Improved Fatigue Were the Main Impacts of Severe Lockdown in Non- COVID Infected Australian Fibromyalgia Patients
Benjamin Worcester¹, Emma Guymer² and Geoffrey Littlejohn², ¹Monash Health, Melbourne, Australia, ²Monash University, Melbourne, Australia
Background/Purpose: To gauge the impact of severe COVID-19 related lockdown restrictions on the mental and physical wellbeing of Australian fibromyalgia patients and their recovery following…

« Previous Page
1
…
4
5
6
7
8
…
23
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.